GIZ943, also known as [177Lu] Lu-EVS459, is a radioligand therapy that targets cells that express folate receptor alpha (FRα). The spokesperson said Novartis stopped development “based on an ...

The 177Lu-PSMA-617 treatment allows for more patients to benefit from the treatment. It enables doctors to determine how well a treatment is actually working. Patients have superior disease ...

Trial 1201 is designed to investigate the pretargeted delivery of the CD38-SADA protein that binds with high affinity to lymphoma cells, followed by the administration of a radioactive 177Lu-DOTA ...

PSMA-delay castration (DC): An open-label, multicenter, randomized phase 3 study of [177Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate ...

which if it reaches the market would be a rival to Novartis’ Lutathera (lutetium [177Lu] oxodotreotide), approved as a second-line therapy for GEP-NETs and due to be filed shortly as first-line ...

The biotech is trying to pick itself up in the wake of the failure of the PARADIGME study of Betalutin (177Lu lilotomab satetraxetan) – an anti-CD37 antibody radionuclide conjugate being tested ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

except for the bladder and kidney as expectedTreatment with 177Lu-RAD202 results in a relevant tumor volume reduction and survival benefit, further pronounced with fractionated therapy vs single ...

The rally followed the announcement of a significant milestone for the company’s clinical-stage radiotherapeutic candidate, 177Lu-RAD204. Radiopharm has received approval from the Data and Safety ...

Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based ... Radiopharm Theranostics - (GLOBE NEWSWIRE) May 12, 2025 ...